🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This work should reassure patients that when delays to treatment are required to recover from toxicity this is not detrimental to treatments prolonging their life. @pinkiechambers doi.org/10.1093/oncolo…

This review summarizes a practical approach to the management of metastatic ROS1 fusion-positive NSCLC, integrating the most up-to-date, evolving evidence behind ROS1 inhibitors and beyond. #ROS1 #LCSM JessicaJLinMD doi.org/10.1093/oncolo…

Could you be The Oncologist's next Deputy Editor? We are particularly interested in applicants with expertise in breast, lung, or gastrointestinal cancer. Learn more and apply by May 9th to be considered: oxford.ly/4j4J3Rn

Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study Fernando Sabino, MD, PhD doi.org/10.1093/oncolo…

This study on NIVO-RELA in advanced melanoma found an ORR of 39% & median PFS of 5.3 months. Notably, 1L treatment had an ORR of 58% & median PFS of 11 months. Promising real-world results! #Melanoma #Oncology Sach Thakker Jafar Al-Mondhiry, MD, MA Inova Schar Cancer Institute doi.org/10.1093/oncolo…

This meta-analysis highlights the different prognostic outcomes of recurrent/metastatic #HNSCC between HPV+ and HPV− populations, underscoring the need for new outcome benchmarks for HPV+ patients. JONG CHUL PARK doi.org/10.1093/oncolo…

"First do no harm" may be outdated in modern oncology. "First hasten to help" may be the better guiding principle—balancing curative therapies with compassionate, patient-centered care and shared decision-making. doi.org/10.1093/oncolo…

In this real-world study involving patients with HER2+ metastatic #BreastCancer, about 25% died or stopped 1L therapy without further treatment. Overall survival was just over 3 years, emphasizing the need for more effective early-line therapies. #bcsm doi.org/10.1093/oncolo…

Calling all #AACR25 attendees! If you are feeling inspired by the event, don't miss your chance to make your mark on the field of oncology research. Apply to be The Oncologist's next Deputy Editor by May 9th to get involved ✍️: oxford.ly/3S3DzKI

Deferred cytoreductive nephrectomy after #ICI therapy in metastatic #RCC shows promising results, w/ 67% of pts having a partial radiological response & 54% discontinuing systemic therapy. Extensive necrosis may be a key marker for durable responses. doi.org/10.1093/oncolo…

In this scoping review of #AI 🤖 in oncology: #LLM show promise for clinical decision & patient info. 🚧in reliability, hallucinations, and clinician oversight. More studies needed 📊 doi.org/10.1093/oncolo…

Early phase trials: the perils of nonpublication Adrian Sacher, M.D. Susan Bates doi.org/10.1093/oncolo…

In #pancsm adding #PERT 💊helped ⬆️ nutrition, ⬇️weight loss, and significantly ⬆️ #OS. This highlights the critical role of treating exocrine pancreatic insufficiency to optimize outcomes in advanced #pancsm patients #GIonc doi.org/10.1093/oncolo…

'Dr Amit Mahipal et al describe BRAF mut 🎯4.4% of non #crcsm #GIonc cancers, #BRAFV600E most common #hpbcsm. 🩸Liquid biopsy reliably detects‼️ #BRAF status showed mixed #OS, and use of BRAF inhibitors ⬇️ despite approvals. 'Sakti Chakrabarti, MD doi.org/10.1093/oncolo…

Results of the first real-world study of 1st-line CGD in patients w/ BTC w/ early relapse. Analysis suggests that this group can benefit from CGD in terms of OS, PFS, and ORR, with a good safety profile. andrea casadei gardini #Cholangiocarcinoma #Immunotherapy doi.org/10.1093/oncolo…

Benchmark study evaluating adequacy and success rates of comprehensive genomic profiling in tissue and plasma samples in a real-world setting. Douglas Lin, MD PhD doi.org/10.1093/oncolo…

Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma Karam Khaddour Insco Lab doi.org/10.1093/oncolo…

Complete response to multimodal temporal therapy in adv pancreatic cancer provides proof-of-concept for the Nant Cancer Vaccine: tumor-targeted chemotherapy + IL-15 superagonist Anktiva & natural killer cell immunotherapy to induce immunogenic cell death. doi.org/10.1093/oncolo…

Opioid use and adverse health effects in breast cancer survivors Kaiser Permanente Research doi.org/10.1093/oncolo…

Risk-sharing agreement (RSA) study reveals that RSAs alleviate financial burden of immunotherapy, fostering a more sustainable healthcare model with up to 40% cost reduction. Oscar Arrieta doi.org/10.1093/oncolo…